| Treatment of retinitis pigmentosa using engineered meganucleases |
2023-8-03 |
2023-8-24 |
|
| Co-stimulatory domains for use in genetically-modified cells |
2023-5-10 |
2023-7-27 |
|
| Engineered meganucleases with recognition sequences found in the human T cell … |
2023-4-03 |
2023-6-15 |
|
| Engineered meganucleases with recognition sequences found in the human beta-2 … |
2023-4-03 |
2023-4-27 |
|
| Engineered meganucleases specific for recognition sequences in the PCSK9 gene |
2023-3-16 |
2023-6-22 |
|
| Optimized polynucleotides for protein expression |
2023-1-06 |
2023-7-13 |
|
| Methods for cancer immunotherapy |
2022-12-09 |
2023-6-15 |
|
| Rationally-designed single-chain meganucleases with non-palindromic recognition … |
2022-11-25 |
2023-3-07 |
|
| Self-limiting viral vectors encoding nucleases |
2022-11-22 |
2023-6-22 |
|
| Methods for cancer immunotherapy |
2022-11-15 |
2023-5-25 |
|
| Methods for immunotherapy |
2022-11-03 |
2023-5-11 |
|
| Nucleic acid molecules encoding an engineered antigen receptor and an … |
2022-11-01 |
2023-2-14 |
|
| Gene editing methods for treating alpha-1 antitrypsin (aat) deficiency |
2022-10-19 |
2023-4-27 |
|
| Gene editing methods for treating alpha-1 antitrypsin (aat) deficiency |
2022-10-19 |
2023-4-27 |
|
| Combinations of anti-bcma car t cells and gamma secretase inhibitors |
2022-10-13 |
2023-4-20 |
|
| Dystrophin gene exon deletion using engineered nuclease |
2022-9-28 |
2023-1-10 |
|
| Modified epidermal growth factor receptor peptides for use in genetically- … |
2022-9-19 |
2023-6-08 |
|
| Compositions and methods for sequential stacking of nucleic acid sequences into … |
2022-9-16 |
2023-6-08 |
|
| Engineered meganucleases having specificity for recognition sequences in the … |
2022-9-13 |
2023-2-16 |
|
| Genetically modified cells comprising a modified human t cell receptor alpha … |
2022-8-30 |
2022-12-06 |
|
| Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir … |
2022-8-17 |
2023-9-07 |
|
| Recognition sequences for i-crei-derived meganucleases and uses thereof |
2022-7-13 |
2023-3-23 |
|
| Precise deletion of chromosomal sequences in vivo and treatment of nucleotide … |
2022-6-17 |
2023-6-29 |
|
| Compositions and methods for generating male sterile plants |
2022-4-22 |
2022-10-27 |
|
| Engineered meganucleases that target human mitochondrial genomes |
2022-4-22 |
2022-10-27 |
|
| Engineered meganucleases that target human mitochondrial genomes |
2022-4-22 |
2022-10-22 |
|
| Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir … |
2022-3-14 |
2022-6-30 |
|
| Engineered nucleases useful for treatment of hemophilia a |
2022-3-10 |
2022-6-23 |
|
| Genetically-modified t cells comprising modified intron in t cell receptor … |
2022-2-16 |
2022-5-24 |
|
| Engineered meganucleases specific for recognition sequences in the hepatitis b … |
2022-2-04 |
2022-8-04 |
|
| Modulation of tgf beta signaling in genetically-modified eukaryotic cells |
2022-1-28 |
2022-8-04 |
|
| Methods and products for producing engineered mammalian cell lines with … |
2022-1-27 |
2022-10-20 |
|
| Engineered meganucleases having specificity for a recognition sequence in the … |
2022-1-07 |
2022-7-14 |
|
| Engineered meganucleases having specificity for recognition sequences in the … |
2021-11-12 |
2023-6-22 |
|
| Optimization of engineered meganucleases for recognition sequences |
2021-11-01 |
2022-1-01 |
|
| Lipid nanoparticle compositions |
2021-10-06 |
2022-4-14 |
|
| Optimized engineered meganucleases having specificity for a recognition … |
2021-9-20 |
2022-2-24 |
|
| Rationally-designed single-chain meganucleases with non-palindromic recognition … |
2021-9-20 |
2021-10-14 |
|
| Engineered meganucleases having specificity for a recognition sequence in the … |
2021-8-20 |
2023-6-28 |
|
| Antibodies and fragments specific for b-cell maturation antigen and uses … |
2021-8-10 |
2023-6-14 |
|
| Methods for immunotherapy |
2021-5-14 |
2021-11-18 |
|
| Methods for immunotherapy |
2021-5-14 |
2023-6-22 |
|
| Treatment of retinitis pigmentosa using improved engineered meganucleases |
2021-5-11 |
2021-11-18 |
|
| Self-limiting viral vectors encoding nucleases |
2021-5-10 |
2021-11-18 |
|
| Recombinant adeno-associated virus compositions and methods for producing and … |
2021-2-05 |
2021-8-12 |
|
| Optimized engineered meganucleases having specificity for a recognition … |
2020-12-04 |
2023-2-02 |
|
| Methods for cancer immunotherapy |
2020-12-03 |
2021-6-10 |
|
| Cd20 chimeric antigen receptors and methods of use for immunotherapy |
2020-10-30 |
2021-5-06 |
|
| Optimized engineered nucleases having specificity for the human t cell receptor … |
2020-10-08 |
2020-11-30 |
|
| Compositions and methods for tcr reprogramming using fusion proteins |
2020-8-21 |
2021-2-25 |
|
| Lymphodepletion dosing regimens for cellular immunotherapies |
2020-8-20 |
2022-3-31 |
|
| Methods of preparing populations of genetically-modified immune cells |
2020-4-03 |
2020-10-08 |
|
| Genetically-modified cells comprising a modified transferrin gene |
2020-1-10 |
2021-11-17 |
|
| Genetic modification of the hydroxyacid oxidase 1 gene for treatment of primary … |
2019-12-20 |
2022-3-24 |
|
| Engineered nucleases that target human and canine factor viii genes as a … |
2018-11-01 |
2020-9-24 |
|
| User interface display method of terminal, and terminal |
2018-6-25 |
2022-10-25 |
2022-10-25 |
| Methods for producing a complex transgenic trait locus |
2018-6-13 |
2018-10-25 |
|
| Methods for reducing dna-induced cytotoxicity and enhancing gene editing in … |
2018-4-30 |
2020-6-18 |
|
| Temperature-Dependent Meganuclease Activity |
2013-7-23 |
2013-12-19 |
|
| Rationally-designed meganucleases with recognition sequences found in dnase … |
2013-5-01 |
2013-8-29 |
|
| Fusion molecules of rationally-designed dna-binding proteins and effector … |
2010-10-28 |
2011-5-26 |
|
| Rationally-designed meganucleases for maize genome engineering |
2010-9-10 |
2011-5-12 |
|